Cytosorbents is engaged in the treatment of life-threatening conditions in the intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology. Co. has several products commercialized and in development based on this technology platform. CytoSorb, Co.'s primary product, is approved in the European Union as an extracorporeal cytokine absorber, designed to reduce the cytokine storm that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. The CTSO stock yearly return is shown above.
The yearly return on the CTSO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CTSO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|